Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn&apos;s Disease Patients

Further Publications

A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch

Am J Gastroenterol

Barnes EL, Raffals L, Qazi T, Deepak P, Chang S, Beniwal-Patel P, Higgins PD, Cross RK, Barr JI, Anderson C, Long MD, Herfarth HH, Dubinsky M, Kappelman MD, Kayal M

doi: 10.14309/ajg.0000000000003608

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Inflammatory Bowel Disease

Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study

Clin Gastroenterol Hepatol

Devi J, Xu A, Stone M, Patel A, Khan A, Reddy N, Klein J, Chowla N, Benson C, Luu BC, Huang K, Jaiprada F, Fenster M, Ungaro R, Pekow J, Johnson AM, Yarur AJ, Shukla R, Huecker J, Bishu S, REBOOT IBD consortium, Deepak P

doi: 10.1016/j.cgh.2025.01.012

Inflammatory Bowel Disease

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Inflamm Bowel Dis

Ertem FU, Rivers CR, Ghaffari AA, Watson AR, Tang G, Schwartz M, Johnston E, Barrie A, Harrison J, Dueker JM, Hartman D, Binion DG

doi: 10.1093/ibd/izae137

Inflammatory Bowel Disease

Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab

Adv Ther

Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Lefebvre P, Kerner C, Pilon D

doi: 10.1007/s12325-024-02963-1

Inflammatory Bowel Disease

The Effectiveness of second-and-third line biologics in perianal Crohn's disease - a multicenter propensity score-matched study

J Crohns Colitis

Shani U, State M, Mateescu RB, Davidoiu AM, Negreanu L, Silva I, Magro F, Lees CW, Plevris N, Roblin X, Castellet-Farrús S, Gonzalez Lama Y, Wang S, Abad C, Imperatore N, Lukas M, Vojtechova G, Ukashi O, Ben-Horin S, Nancey S, Savarino E, Stawczyk-Eder K, Eder P, Toskas A, Kamperidis N, Arebi N, Farkas B, Farkas K, Pipek B, Falt P, Karmiris K, Nikolaou P, Krznaric Z, Brinar M, Hoentjen F, van Lierop L, Barreiro-de Acosta M, Zaborowska M, Zagorowicz E, Pugliese D, Cuccia G, Truyens M, Kopylov U

doi: 10.1093/ecco-jcc/jjaf099

Inflammatory Bowel Disease

Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease

BMC Gastroenterol

Karki C, Hantsbarger G, Turkstra E, Fenu E, Genenz K, Gilaberte I, Panés J

doi: 10.1186/s12876-024-03513-3

Inflammatory Bowel Disease

MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease

Insights Imaging

Sakai NS, Plumb AA, Ahmed N, Chowdhury K, Kilic Y, Hameed M, Patel A, Bhagwanani A, Helbren E, Hyland R, Bhatnagar G, Sidhu H, Lambie H, Franklin JM, Mohsin M, Thomson E, Boone D, Tolan D, Rahman S, Ding N, Moran GW, Bloom S, Hart A, Menys A, Travis S, Halligan S, Taylor SA, Motility trial investigators

doi: 10.1186/s13244-025-01930-w

Inflammatory Bowel Disease

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

J Crohns Colitis

Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S

doi: 10.1093/ecco-jcc/jjaf052

Gastroenterology

Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients

Related content

A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab

The Effectiveness of second-and-third line biologics in perianal Crohn's disease - a multicenter propensity score-matched study

Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease

MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study